...
机译:长期随访的共鸣相3试验Ibrutinib Vs atatumumab
Ohio State Univ Ctr Comprehens Canc Columbus OH 43210 USA;
Leeds Teaching Hosp St James Inst Oncol Leeds W Yorkshire England;
UC Irvine Chao Family Comprehens Canc Ctr Irvine CA USA;
Zucker Sch Med Hofstra Northwell Lake Success NY USA;
Vanderbilt Ingram Canc Ctr Nashville TN USA;
Stanford Univ Sch Med Stanford CA 94305 USA;
Peter MacCallum Canc Ctr Dept Haematol Melbourne Vic Australia;
Royal North Shore Hosp Sydney NSW Australia;
Med Univ Vienna Div Hematol &
Hemostaseol Vienna Austria;
Univ Rochester Med Ctr Rochester NY 14642 USA;
New York Presbyterian Hosp Weill Cornell Med Coll New York NY USA;
UCSD Moores Canc Ctr San Diego CA USA;
Beaumont Hosp Dublin Ireland;
Hosp Santa Creu St Pau Barcelona Spain;
Osped Niguarda Ca Granda Milan Italy;
Swedish Canc Inst Hematol Malignancies Program Seattle WA USA;
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
Ohio State Univ Ctr Comprehens Canc Columbus OH 43210 USA;
Pharmacyclics LLC Sunnyvale CA USA;
Pharmacyclics LLC Sunnyvale CA USA;
Pharmacyclics LLC Sunnyvale CA USA;
Dana Farber Canc Inst CLL Ctr Boston MA 02115 USA;
机译:长期随访的共鸣相3试验Ibrutinib Vs atatumumab
机译:在先前经过治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL / SLL)中,Ibrutinib与atumumab:随机阶段III的结果产生(TM)(PCYC-1112)试验结果
机译:CLL / SLL患者的一线Ibrutinib治疗的长期疗效和安全性:从第3期的5年后续转发-2研究
机译:在MADIT II患者常规随访的预期多中心比较试验:额外访问和成本影响
机译:在生命早期补充略微基于脂质的营养补充剂对加纳学龄前儿童的甜味偏爱,甜食和饮料偏爱或消费的影响:一项随机对照试验的随访
机译:一线依鲁替尼治疗CLL / SLL患者的长期疗效和安全性:RESONATE-2 3期研究随访5年
机译:教师意见建议,对CLL / SLL患者的一线Ibrutinib治疗的长期疗效和安全性:从第3期的5年后续进行共振-2研究。